Loading clinical trials...
Loading clinical trials...
A Multicenter, Open-label, Phase 1a/b Study of HC-7366 in Subjects With Advanced Solid Tumors
Conditions
Interventions
HC-7366
Locations
7
United States
UC San Diego Moores Cancer Center
La Jolla, California, United States
University of Colorado Anschutz Medical Campus
Aurora, Colorado, United States
Washington University School of Medicine
St Louis, Missouri, United States
Sarah Cannon Research Institute /Tennessee Oncology
Nashville, Tennessee, United States
Vanderbilt-Ingram Cancer Center
Nashville, Tennessee, United States
The University of Texas M.D. Anderson Cancer Center
Houston, Texas, United States
Start Date
February 23, 2022
Primary Completion Date
February 9, 2024
Completion Date
March 1, 2024
Last Updated
March 8, 2024
NCT05671510
NCT03340506
NCT04389632
NCT04895709
NCT05952934
NCT07485114
Lead Sponsor
HiberCell, Inc.
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions